AIM ImmunoTech (AIM) announced that it received a notice from the NYSE American, notifying the company that it is no longer in compliance with NYSE American continued listing standards. This is an issue previously disclosed in our most recent Report on Form 10-Q. Specifically, the letter states that the company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech expands patent portfolio with new Netherlands patent
- Kellner Group says former AIM ImmunoTech executive supports nominees
- Kellner Group urges AIM ImmunoTech stockholders to vote for its nominees
- AIM ImmunoTech says Glass Lewis recommends shareholders vote for nominees
- Kellner Group announces former CEO to join SAB if nominees elected